Literature DB >> 16102474

The impact of type 2 diabetes and peripheral arterial disease on quality of life.

Roberta K Oka1, Mark G Sanders.   

Abstract

Peripheral arterial disease (PAD) is associated with impaired walking distance as the result of claudication and reduced quality of life (QOL). Diabetes mellitus (DM) is commonly associated with PAD. The combined effect of DM and PAD versus PAD alone on walking distance and QOL is not well understood. This prospective, descriptive study examined walking distance and QOL associated with DM and PAD compared with PAD alone. Walking distance was assessed by an exercise treadmill test to determine initial claudication distance and absolute claudication distance and by self-report using the Walking Impairment Questionnaire. QOL was measured using the Short Form-36. The overall sample consisted of 92 men and women with PAD and DM or PAD alone. Of the total sample, 74 participants had PAD with ABI less than 0.9 mm Hg and 18 subjects had PAD and uncontrolled DM with hemoglobin A1c 7.0 mg/dL or greater. The mean age was 72 years (standard deviation [SD] = 7) for the PAD only group and 75 years (SD = 8) (not significant) for the PAD and DM groups. Initial claudication distance was greater in subjects with PAD only (186.9 m, SD = 136.4) than in diabetic subjects with PAD (127.3 m, SD = 70.0, P = .01). Absolute claudication distance was higher in patients with PAD only (461.3 m, SD 308) than in diabetic subjects with PAD (279.1 m, SD = 100, P = .01). Self-reported walking speed was reduced in patients with DM and PAD compared with patients with PAD only (P = .05). Diabetic patients with PAD reported impaired role function (P = .007), general health (P = .03), and social function (P = .04) compared with patients with PAD only. We conclude that DM has a significant detrimental impact on walking distance and QOL in patients with PAD. These findings suggest that diabetic patients with PAD are at greater risk for experiencing social isolation, impaired role function, reduced overall perceptions of general health, and impaired functional capacity. Future studies with larger sample sizes are needed to identify factors that contribute to these perceptions in diabetic patients with PAD.

Entities:  

Mesh:

Year:  2005        PMID: 16102474     DOI: 10.1016/j.jvn.2005.03.032

Source DB:  PubMed          Journal:  J Vasc Nurs        ISSN: 1062-0303


  6 in total

1.  Effect of type 2 diabetes mellitus on exercise intolerance and the physiological responses to exercise in peripheral arterial disease.

Authors:  S Green; C D Askew; P J Walker
Journal:  Diabetologia       Date:  2007-01-20       Impact factor: 10.122

Review 2.  Quality of life in glaucoma and three other chronic diseases: a systematic literature review.

Authors:  Tim Mills; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

3.  Experience Implementing Supervised Exercise Therapy for Peripheral Artery Disease.

Authors:  Dereck L Salisbury; Mary O Whipple; Marsha Burt; Rebecca Brown; Ryan J Mays; Mark Bakken; Diane Treat-Jacobson
Journal:  J Clin Exerc Physiol       Date:  2019-03

4.  Quality of life in patients with intermittent claudication.

Authors:  A E Harwood; J P Totty; E Broadbent; G E Smith; I C Chetter
Journal:  Gefasschirurgie       Date:  2017-04-18

5.  Diabetes mellitus and intermittent claudication: a cross-sectional study of 920 claudicants.

Authors:  Francisco S Lozano; José R González-Porras; José R March; José M Lobos; Eduardo Carrasco; Eduardo Ros
Journal:  Diabetol Metab Syndr       Date:  2014-02-17       Impact factor: 3.320

6.  Association of Diabetes Mellitus With Health Status Outcomes in Patients With Peripheral Artery Disease: Insights From the PORTRAIT Registry.

Authors:  Krishna K Patel; Hani Alturkmani; Kensey Gosch; Carlos Mena-Hurtado; Mehdi H Shishehbor; Poghni A Peri-Okonny; Mark A Creager; John A Spertus; Kim G Smolderen
Journal:  J Am Heart Assoc       Date:  2020-11-06       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.